Interestingly, both evaluated CpG sites showed significant hypomethylation in ccRCC compared with NAT (p<0.001) and, inversely, CTLA4 mRNA expression was increased in ccRCC versus NAT (figure 1B–D). The gene discussed is BRD2; the disease is nonpapillary renal cell carcinoma.